RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Satisfaction and treatment burden among early adopters of long-acting injectable cabotegravir-rilpivirine with and without viremia in three US ryan white clinics
Christopoulos, K. A., Beckert, A., McCracken, C., Dance, K., Plotkin, S., Collins, L. F., McNulty, M. C., Hickey, M. D., Johnson, M. O., Mody, A., Erguera, X. A., Koester, K. A., Liegeon, G., Salazar, J., Gutierrez, J., Grochowski, J., Dilworth, S. E., Neilands, T. B., Montgomery, E. T., & Colasanti, J. A. (2026). Satisfaction and treatment burden among early adopters of long-acting injectable cabotegravir-rilpivirine with and without viremia in three US ryan white clinics. Open Forum Infectious Diseases, 13(9), ofag559. Article ofag559. https://doi.org/10.1093/ofid/ofag559
Among underserved people with HIV with a median of one year of long-acting cabotegravir-rilpivirine use, including those starting with viremia due to adherence challenges, we found higher satisfaction and lower treatment burden compared to daily oral ART, although nearly half preferred another dosing modality and/or a longer dosing interval.
RTI shares its evidence-based research - through peer-reviewed publications and media - to ensure that it is accessible for others to build on, in line with our mission and scientific standards.
